Next-Gen Cancer Detection: Protein Pattern Recognition, AI-Supported
Designed to reduce uncertainty and unnecessary procedures through more accurate testing
Who Are We?
Our Mission
Our Technology
Our Mission
At Definitive Diagnostics, our mission is to target large and expensive gaps in cancer care by improving the reliability and
affordability of cancer detection for millions of patients. Our goal is to accelerate timely diagnosis and eliminate unnecessary waste from false test results.
Our Science
Our Technology
Our Mission
Definitive Diagnostics utilizes a patented, protein-based method that measures 16 abundant protein/immune biomarkers forming cancer-specific patterns. Independent validation: 99% sensitivity (Stage 0 breast), 97% specificity, 98% ToO.
In early testing, we've detected cancer as early as Stage 0 in breast cancer and at Stage I in lung, colorectal, ovarian, and pancreatic cancers.
Our Technology
Our Technology
Our Technology
We're merging our protein platform with AI to enhance performance of our pattern detection technology while preparing for future discovery into other cancers and subtypes. As we expand our patient data pool, our technology will allow us to discover new patterns to expand and speed diagnosis for millions of early stage patients.